Mallinckrodt is set to be in the hands of its lenders after a US bankruptcy court confirmed the company’s restructuring plan, which includes more than halving the $1.7bn previously promised to victims of the US opioid crisis.
Mallinckrodt has won approval from a US district court to emerge from its second bankruptcy in just three years, allowing the firm to extinguish approximately $1.9bn of total funded debt from its balance sheet while rowing back significantly on the $1.7bn the firm had previously agreed to pay to settle claims over its role in the US opioid crisis.
With legal proceedings for the Ireland-domiciled firm set to take between two and three months to complete, Mallinckrodt is hopeful...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
